OP0252 ARTHRITIS AND ENTHESITIS IN THE HIP AND PELVIS REGION IN SPONDYLOARTHRITIS – VALIDATION OF TWO WHOLE-BODY MRI METHODS
Authors: M. Wetterslev, R. G. Lambert, W. P. Maksymowych, I. Eshed, S. Juhl Pedersen, P. Bird, M. Stoenoiu, S. Krabbe, A. J. Mathew, V. Foltz, F. Gandjbakhch, J. Paschke, G. De Marco, H. Marzo-Ortega, P. Carron, A. E. F. Poulsen, J. L. Jaremko, P. G. Conaghan, M. Østergaard
Journal: Annals of the Rheumatic Diseases (2021)

Background: Whole-body MRI (WB-MRI) allows assessment of the overall inflammation in arthritis patients, including joint and entheses. To enhance the use of WB-MRI in clinical trials, the OMERACT MRI in Arthritis Working Group developed the OMERACT MRI Whole-body score for Inflammation in Peripheral joints and Entheses in inflammatory arthritis (MRI-WIPE) [1]. This has been validated for the entire body, including the hip/pelvis region, but not for each individual region. More detailed scoring systems exist for heels, hands and feet but although hip arthritis is a key cause of functional impairment in spondyloarthritis (SpA), no detailed scoring system has been published for use in SpA. The Hip Inflammation Magnetic Resonance Imaging Scoring System (HIMRISS) was developed and validated in osteoarthritis showing good reliability. Objectives: To validate reliability, correlation and responsiveness of two WB-MRI scores for the hip/pelvis region in SpA. Methods: Inflammation in the hip/pelvis region was assessed on coronal WB-MRIs in 4 iterative multi-reader exercises using MRI-WIPE for the hip/pelvis region and HIMRISS (Figure 1). In final exercises, images (axial/peripheral SpA and psoriatic arthritis) were obtained before and after TNF-inhibitor. Results: In final exercises reliability was mostly good for the best calibrated readers. Median single-measure intraclass correlation coefficients were 0.58-0.65 (WIPE osteitis), 0.10-0.88 (HIMRISS osteitis), 0.38-0.72/0.52-0.60 (WIPE synovitis/effusion) and 0.68-0.89/0.78-0.85 (HIMRISS synovitis/effusion) (Table 1). The methods correlated significantly for status in osteitis (0.72, p=0.019) and for synovitis/effusion status (0.83, p=0.003) and change (0.73, p=0.017) (Table 1). In exercise 4 Wilcoxon signed-rank test showed significant change in osteitis between timepoints using WIPE hip/pelvis and SRM was large (1.23), while lower for WIPE synovitis/effusion and HIMRISS. Table 1. MRI-WIPE hip/pelvis and HIMRISS interreader reliability for OMERACT exercises 3-4 MRI-WIPE hip/pelvis HIMRISS Osteitis Synovitis/effusion Osteitis Synovitis/effusion Variables No. patients (cases ) Type of score Mean score ICC Mean score ICC Mean score ICC Mean score ICC Exercise 3 9 readers 11 Status 2.3 (0-10) 0.69 (0.23-0.93) 1.4 (0-4) 0.58 (-0.06-0.96) 8.2 (1-60) 0.84 (0.56-0.99) 12.8 (3-25) 0.52 (0.00-.91) 11 Change -0.2 (-1-1) NA -0.2 (-3-1) 0.50 (0.10-0.87) -0.35 (-3-1) NA -1.8 (-17-10) 0.50 (-0.05-0.89) Exercise 3 3 readers 11 Status 1.8 (0-10) 0.63 (0.46-0.93) 1.7 (0-5) 0.60 (0.34-0.80) 6.6 (0-65) 0.88 (0.77-0.94) 12.8 (2-28) 0.89 (0.87-0.91) 11 Change -0.12 (-1-1) NA -0.12 (-3-2) 0.60 (0.48-0.83) -0.7 (-7-0) NA -1.6 (-21-8) 0.78 (0.70-0.87) Exercise 4 9 readers 10 (1-10) Status 1.2 (0-4) 0.21 (-0.39-0.91) 1.1 (0-2) 0.19 (-0.31-0.69) 1.8 (0-6) 0.07 (-0.17-0.83) 16.4 (9-23) 0.31 (0.00-0.89) 10 (11-20) Status 1.6 (0-6) 0.51 (-0.08-0.99) 1 (0-3) 0.40 (-0.17-0.88) 3.5 (1-8) 0,08 (-0.21-0.95) 11.2 (5-24) 0.49 (0.00-0.94) 10 11-20) Change -0.4 (-2-0) NA -0.39 (-2-0) 0.22 (-0.68-0.83) -2.2 (-7-2) NA -5.2 (-18-0) 0.57 (0.02-0.92) 20 (1-20) Status 1.4 (0-6) 0.41 (-0.35-0.92) 1.0 (0-3) 0.27 (-0.07-0.75) 2.7 (0-9) 0.09 (-0.17-0.85) 13.8 (5-25) 0.45 (0.01-0.90) Exercise 4 3 readers 10 (1-10) Status 0.8 (0-4) 0.29 (0.01-0.78) 1.3 (0-2) -0.02 (-0.29-0.12) 0.4 (0-2) -0.04 (-0.04-0.04) 15.8 (5-26) 0.73 (0.59-0.89) 10 (11-20) Status 1.8 (0-9) 0.65 (0.52-0.76) 1.2 (0-4) 0.72 (0.62-0.81) 1.7 (0-5) 0.06 (-0.17-0.35) 9.2 (2-26) 0.68 (0.53-0.88) 10 (11-20) Change -0.6 (-2-0) NA -0.5 (-3-1) 0.52 (0.49-0.55) -0.2 (-2-1) NA -2.8 (-19-6) 0.85 (0.82-0.88) 20 (1-20) Status 1.3 (0-9) 0.58 (0.43-0.69) 1.2 (0-4) 0.38 (0.31-0.44) 1.0 (0-5) 0.10 (-0.09-0.33) 12.5 (2-26) 0.73 (0.69-0.77) Sum scores and ICCs are mean (range). ICC is 2-way mixed, single measure, by absolute agreement. Conclusion: MRI-WIPE and HIMRISS may be useful tools in modular WB-MRI evaluation of hip/pelvis inflammation in clinical trials in SpA. References: [1]Krabbe S et al. J Rheum. 2019;46(9):1215-21 [2]Jaremko JL et al. J Rheum. 2019;46(9)1239-42 Acknowledgements: We thank CARE Arthritis Limited (carearthritis.com) for help with setting up the web-based scoring interface, scoring exercises, and the web-based meetings. We acknowledge the contribution of SIG (Special Interest Group) participants at the virtual OMERACT meeting October 29, 2020. HMO, GDM and PGC are supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, United Kingdom. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Disclosure of Interests: Marie Wetterslev: None declared, Robert G Lambert Consultant of: Parexel and Pfizer, Walter P Maksymowych Speakers bureau: AbbVie, Janssen, Novartis, Pfizer and UCB, Consultant of: AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Novartis, Pfizer and UCB, Iris Eshed: None declared, Susanne Juhl Pedersen Speakers bureau: MSD, Pfizer, AbbVie, Novartis and UCB, Consultant of: AbbVie and Novartis, Grant/research support from: AbbVie, MSD, and Novartis, Paul Bird Speakers bureau: Janssen, Abbvie, UCB, Celgene, BMS, Novartis, Pfizer, Gilead, Eli-Lilly, Consultant of: Janssen, Abbvie, UCB, Celgene, BMS, Novartis, Pfizer, Gilead, Eli-Lilly, Maria Stoenoiu: None declared, Simon Krabbe: None declared, Ashish Jacob Mathew: None declared, Violaine Foltz: None declared, Frederique Gandjbakhch: None declared, Joel Paschke: None declared, Gabriele De Marco: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Grant/research support from: Janssen and Novartis, Philippe Carron Speakers bureau: Pfizer, MSD, Novartis, BMS, AbbVie, UCB, Eli Lilly, Gilead and Celgene, Consultant of: Pfizer, MSD, Novartis, BMS, AbbVie, UCB, Eli Lilly, Gilead and Celgene, Grant/research support from: UCB, MSD and Pfizer, Anna Enevold Fløistrup Poulsen: None declared, Jacob L Jaremko: None declared, Philip G Conaghan Speakers bureau: AbbVie, BMS, Eli Lilly, Flexion Therapeutics, Galapagos, Gilead, Novartis, Pfizer, Regeneron, Stryker, Consultant of: AbbVie, BMS, Eli Lilly, Flexion Therapeutics, Galapagos, Gilead, Novartis, Pfizer, Regeneron, Stryker, Mikkel Østergaard Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Consultant of: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/research support from: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB